

Applicants : Aharoni, et al.  
Serial No. : 09/768,872  
Filed : January 23, 2001  
Page 2

**In the Claims**

Please amend the claims by replacing all prior versions, and listings, of claims pursuant to 37 C.F.R. §1.121(c) as follows:

1-15. (Canceled)

16. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an therapeutically~~therapeutically~~ effective amount of a mixture of terpolymers, each terpolymer consisting of tyrosine, alanine and lysine.

17-18. (Canceled)

19. (Previously Presented) The pharmaceutical composition of Claim 16, wherein said tyrosine is present in a mole fraction of about 0.005 to about 0.250; said alanine is present in a mole fraction of about 0.3 to about 0.6; and lysine is present in a mole fraction of about 0.1 to about 0.5.

20. (Previously Presented) The pharmaceutical composition of Claim 16, wherein said tyrosine is present in a mole fraction of 0.10, said alanine is present in a mole fraction of 0.54, and said lysine is present in a mole fraction of 0.35.

21-31. (Canceled)

32. (Previously Presented) The pharmaceutical composition of Claim 16 wherein said mixture of terpolymers has an average molecular weight of about 2,000 to about 40,000

Applicants : Aharoni, et al.  
Serial No. : 09/768,872  
Filed : January 23, 2001  
Page 3

daltons.

33. (Previously Presented) The pharmaceutical composition of Claim 16 wherein said mixture of terpolymers has an average molecular weight of about 4,000 to about 9,000 daltons.

34.-165. (Canceled)